We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
Read MoreHide Full Article
In a significant move to enhance mental health care accessibility, Neuronetics, Inc. (STIM - Free Report) has entered into an expanded commercial partnership with Transformations Care Network (“TCN”), a mental health care provider. This partnership marks a significant advancement in the field of mental health treatment, particularly for patients suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD).
The financial terms of the deal were not disclosed.
More on the Deal
With Neuronetics designated as the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, the agreement significantly amplifies the availability of NeuroStar TMS treatments.
By combining advanced technologies and treatments, TCN aims to elevate the standard of care for individuals grappling with complex mental health conditions.
Significance of the Deal
The collaboration between Neuronetics and TCN holds particular significance in the realm of treatment-resistant depression. MDD, especially when resistant to conventional treatments, presents a substantial challenge in mental health care. NeuroStar TMS therapy offers a non-invasive alternative that has shown effectiveness where traditional pharmacological interventions have fallen short.
Image Source: Zacks Investment Research
Market Prospects
According to an Imarc Group report, the global mental health treatment market is projected to grow from $435.2 billion in 2023 to $567.3 billion by 2032 at a CAGR of 2.9%. Primary growth drivers include increasing demand, digital advancements, corporate focus on mental well-being, and supportive government policies. With applications across various industries and North America leading the charge, competition remains fierce, emphasizing innovation and quality. Despite challenges like stigma, opportunities lie in technology and telehealth solutions, promising a dynamic future with personalized treatment approaches.
Share Price Performance
Over the past year, shares of STIM have risen 5.9% compared with the industry’s 14% growth.
Zacks Rank and Key Picks
Neuronetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Cardinal Health (CAH - Free Report) , Stryker Corporation (SYK - Free Report) and Cencora, Inc. (COR - Free Report) .
Cardinal Health, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker, carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Cencora, carrying a Zacks Rank #2, reported first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.
COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
In a significant move to enhance mental health care accessibility, Neuronetics, Inc. (STIM - Free Report) has entered into an expanded commercial partnership with Transformations Care Network (“TCN”), a mental health care provider. This partnership marks a significant advancement in the field of mental health treatment, particularly for patients suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD).
The financial terms of the deal were not disclosed.
More on the Deal
With Neuronetics designated as the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, the agreement significantly amplifies the availability of NeuroStar TMS treatments.
By combining advanced technologies and treatments, TCN aims to elevate the standard of care for individuals grappling with complex mental health conditions.
Significance of the Deal
The collaboration between Neuronetics and TCN holds particular significance in the realm of treatment-resistant depression. MDD, especially when resistant to conventional treatments, presents a substantial challenge in mental health care. NeuroStar TMS therapy offers a non-invasive alternative that has shown effectiveness where traditional pharmacological interventions have fallen short.
Image Source: Zacks Investment Research
Market Prospects
According to an Imarc Group report, the global mental health treatment market is projected to grow from $435.2 billion in 2023 to $567.3 billion by 2032 at a CAGR of 2.9%. Primary growth drivers include increasing demand, digital advancements, corporate focus on mental well-being, and supportive government policies. With applications across various industries and North America leading the charge, competition remains fierce, emphasizing innovation and quality. Despite challenges like stigma, opportunities lie in technology and telehealth solutions, promising a dynamic future with personalized treatment approaches.
Share Price Performance
Over the past year, shares of STIM have risen 5.9% compared with the industry’s 14% growth.
Zacks Rank and Key Picks
Neuronetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Cardinal Health (CAH - Free Report) , Stryker Corporation (SYK - Free Report) and Cencora, Inc. (COR - Free Report) .
Cardinal Health, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker, carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.
Cencora, carrying a Zacks Rank #2, reported first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.
COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.